Life Sciences
Adamis announces merger four months after PhII/III miss
In a bid to stay afloat, Adamis Pharmaceuticals will merge with DMK Pharmaceuticals. The merger comes just four months after its stock crashed following…
In a bid to stay afloat, Adamis Pharmaceuticals will merge with DMK Pharmaceuticals. The merger comes just four months after its stock crashed following a Phase II/III trial failure. The company said it was looking at other options, including bankruptcy protection.
The current CEO of DMK, Eboo Versi, will take over as CEO of the combined company once the deal is completed.
“I believe by combining Adamis’ commercial products and development infrastructure with DMK’s clinical-stage programs and library of small molecules, under Dr. Versi’s leadership, the new company will have the potential to develop multiple groundbreaking treatments and ultimately grow shareholder value,” David Marguglio, CEO of Adamis, said in a statement.
Until now, DMK’s work has been “largely” financed by non-dilutive funding from the government, according to a press release, with a focus on treatments for opioid use disorder, like its lead clinical stage product candidate, DPI-125.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….